Drug Type Small molecule drug |
Synonyms AXT 1003, AXT-1003 |
Target |
Mechanism EZH2 inhibitors(Histone-lysine N-methyltransferase EZH2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 04 Sep 2024 | |
Advanced cancer | Phase 1 | CN | 30 Jul 2024 | |
Peripheral T-Cell Lymphoma | Phase 1 | CN | 20 Jul 2023 | |
Extranodal NK-T-Cell Lymphoma | Phase 1 | CN | - | |
Prostatic Cancer | Preclinical | CN | 19 Jul 2022 | |
Sarcoma | Preclinical | CN | 19 Jul 2022 | |
Stomach Cancer | Preclinical | CN | 19 Jul 2022 | |
Follicular Lymphoma | Preclinical | US | 30 Jan 2022 |